Fate Therapeutics, Inc.
3535 General Atomics Court
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell therapies using its proprietary induced pluripotent stem cell (iPSC) product platform. This platform uniquely enables the single-cell selection of a precisely engineered iPSC clone and the subsequent creation and maintenance of a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for consistently and repeatedly manufacturing homogeneous cell products in quantities that support the treatment of many thousands of patients in an off-the-shelf manner. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Stock Symbol: FATE
Stock Exchange: Nasdaq
100 articles with Fate Therapeutics, Inc.
Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies
Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate’s Proprietary iPSC Product Platform
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
Fate Therapeutics Announces First Patient Treated In Protmune PROTECT Clinical Trial For The Prevention Of Graft-Versus-Host Disease
Fate Therapeutics To Webcast Conference Call Reporting Third Quarter 2016 Financial Results On November 7, 2016
Fate Therapeutics Announces Issuance Of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions
Fate Therapeutics Receives FDA Orphan Drug Designation For Protmune In Allogeneic Hematopoietic Cell Transplantation
San Diego's Fate Therapeutics Lands a Deal With Star Scientist to Work on Off-the-Shelf T-Cell Immunotherapies
Fate Therapeutics Announces Issuance Of U.S. Patent On Compositions Of Human Induced Pluripotent Cells
Fate Therapeutics To Host Off-The-Shelf Cancer Immunotherapy Focus Session At 2016 Annual Meeting Of International Society for Stem Cell Research
Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function Of Allogeneic Natural Killer Cell Cancer Immunotherapy
Fate Therapeutics To Webcast Conference Call Reporting First Quarter 2016 Financial Results On May 9, 2016
Fate Therapeutics To Webcast Conference Call Reporting Fourth Quarter And Full Year 2015 Financial Results On March 3, 2016
Fate Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Protmune For Prevention Of Acute Gvhd And CMV Infection